Printer Friendly

Does HCV make HIV infection worse?

HIV makes HCV infection worse. Compared with people infected only with HCV, those burdened by both viruses get cirrhosis faster (1,2) and die sooner. (3,4) Taking combination antiretroviral therapy (cART) eased HIV's baneful impact on HCV progression in a 3567-person meta-analysis, but not completely. (1)

Does HCV infection make HIV infection worse? Studies addressing this question yield different--and sometimes conflicting--answers. No one should be surprised. These studies used different methods to analyze different populations, different endpoints, and different periods (before and after the arrival of cART). And some of the cART-era studies involve more toxic and inconvenient antiretrovirals rarely used today. According to an AIDS Clinical Trials Group (ACTG) team that recently explored these issues, (5) the controversy breaks down this way:

* Natural history studies show that--before HCV/ HIV-coinfected people start cART--their HIV disease progression largely tracks with that of people infected only with HIV. (6-8)

* After people begin cART, some studies found that HCV/HIV-coinfected people have smaller or delayed CD4 gains than HIV-monoinfected people. (9-15)

* A few studies found, though, that CD4 differences between coinfected and monoinfected people wane as cART continues. (16,17)

* And a cluster of other studies found no link between coinfection and dampened CD4 gains. (18-25)

* Three studies that examined the impact of coinfection on virologic response to cART found no link. (10,11,26)

* A 2009 meta-analysis (13) and other studies (27,28) discerned no tie between HCV/HIV coinfection and AIDS-defining endpoints.

* But one study did link coinfection with AIDS endpoints. (29)

This article dissects these and other studies to answer three questions:

1. How does HCV infection affect mortality in people with HIV?

2. How does HCV infection affect progression to AIDS and other clinical outcomes?

3. How does HCV infection affect response to cART?

Answers to these questions have already informed guidelines on caring for people with potential and confirmed HCV/HIV coinfection. Tables 1 and 2 outline current guidelines. A 1-page handout following this article offers HCV/HIV patients 10 pointers on preventing transmission of these viruses and avoiding treatment complications.


The impression that HCV does not affect survival in people with HIV dates to the pre-cART era, when HIV-positive people died of AIDS long before they could die of heart, kidney, or liver disease. Two emblematic studies involve medium-size US HIV cohorts--one largely male and one entirely female. (35,36)

Researchers compared survival in 115 HIV-positive veterans with HCV and 235 without HCV in the HIV Atlanta Veterans Affairs Medical Cohort Study (Table 3). (35) These people were in care at some point from January 1992 to May 1997, and all but 5 were men. Most participants had taken antiretrovirals, but only 20% had taken a protease inhibitor, so this was a largely cART-naive cohort. Multivariate analysis identified no links between antiretroviral treatment history and HCV antibody positivity.

The same proportion of people in the coinfected group and the HIV-only group--70%--had AIDS. (35) Twenty-four people with coinfection (21%) and 46 with HIV alone (20%) died during the study period (Table 3). Cox proportional hazards models discerned no difference between the coinfected group and the monoinfected group in time from HIV diagnosis to death or time from AIDS diagnosis to death. In this group, largely in care before the benefits of cART took hold, HCV coinfection did not shorten survival.

A Women and Infants Transmission Study (WITS) analysis involved 652 women--190 (29%) with HCV and none with an AIDS diagnosis--who enrolled in the cohort when pregnant from 1989 through 1995, before cART arrived. (36) Only 124 women (19%) tried a cART combination during follow-up (with no difference between coinfected and monoinfected women). Forty-three women (7%) died, 26 of them (4%) with out a documented AIDS diagnosis. Cox proportional hazards analysis determined that coinfected women did not have faster progression to an initial class C AIDS diagnosis or death (relative hazard 0.75, 95% confidence interval [CI] 0.37 to 1.53).

AIDS as a king-size competing risk

These two studies (35,36) share a key limitation: The investigators did not report (and perhaps did not know) what caused the deaths in their cohort. Was it AIDS, liver failure, or something else? Knowing the cause of death is critical to understanding whether HCV infection shortens survival in people with HIV because of a statistical bugbear called competing risk. A person who runs a risk of more than one mutually exclusive mortal event--such as death from AIDS and death from HCV-induced liver failure--has competing risks. (37) The risks compete because if one happens, the other can't.

From the dawn of the HIV epidemic until wide use of cART, AIDS became a competing risk as population-shredding as the black death in 1666 London or influenza in 1918 across the globe. Until the mid-1990s HIV-positive men and women died of AIDS in their 30s and 40s--long before they could succumb to heart disease or lung cancer--even if they had relatively high heart or cancer risks. Compared with HIV infection, HCV infection is an indolent disease. About 10 years elapse between untreated HIV infection and AIDS in the United States, (38) and perhaps another 2 years between untreated AIDS and death. (39,40) In contrast, people with untreated HCV infection can live without cirrhosis for 20 to 30 years and sidestep liver failure for years beyond that. (41) So a person infected with both viruses runs a much higher risk of dying from AIDS than from liver disease, even if infected with HCV 5 or 10 years earlier than with HIV.

A pre-cART study from Spain shows how handily AIDS out competes liver disease in coinfected and inadequately treated people. (42) The cohort included 328 antiretroviral-treated people seen from 1989 through 1996--before wide cART use. The group had a median initial CD4 count of 303 cells/[mm.sup.3]. Two thirds (65%) had HCV, 5% HBV, and 3% hepatitis D virus. The researchers did not know whether 36 people (11%) lived or died. Among the remaining people, 67 died. Forty-nine of those 67 (73.1%) died of AIDS, while only 3 (4.5%) died of liver failure and 15 (22.4%) of other causes. As in the two US studies, (35,36) mortality did not differ between people with and without hepatitis virus infection. But AIDS killed 22 times more people than hepatitis in this group receiving inadequate treatment for their viral infections.

cART makes liver disease a top killer

What happened when HCV/HIV-coinfected people started taking three antiretrovirals at the same time? They stopped dying of AIDS as quickly, and growing proportions began living so long with HIV they started dying of other diseases--including liver failure and liver cancer. And study after study began showing that HCV coinfection boosted chances of death in people with HIV. For example, whereas the pre-cART analysis of the Atlanta VA Cohort found that HCV coinfection did not affect survival, (35) an early cART-era analysis of the same group did. (43) The later study involved 970 HIV-positive people in care from January 1997 through May 2001, 306 of whom (32%) had HCV infection (Table 3). About two thirds in each group had AIDS, and CD4 counts when cART began were similar. During follow-up in the later study 67 coinfected people and 72 monoinfected people died, a highly significant difference (21.9% versus 10.8%, P < 0.0001). (43)

Multivariate survival analysis determined that coinfected people had significantly shorter survival after HIV diagnosis than did monoinfected people (hazard ratio [HR] 2.47, 95% CL 1.26 to 4.82, P = 0.0085) (Table 3). (43) Survival after AIDS diagnosis was also significantly shorter in the coinfected group (HR 1.84, 95% CI 1.09 to 3.10, P = 0.022). Taking cART for at least 1 month was independently associated with longer survival after HIV diagnosis (HR 0.25, 95% CI 0.16 to 0.39, P < 0.0001) and after AIDS diagnosis (HR 0.26, 95% CI 0.16 to 0.42, P < 0.0001). HCV coinfection did not affect short- or long-term CD4 recovery in this cohort.

Before long, enough HCV/HIV mortality studies got published to allow meta-analysis. In 2009 researchers analyzed 10 studies from pre-CART days and 27 from the cART era, all of them including HIV-positive people with or without HCV infection. (13) The 10 precART studies (5 US/Canada, 4 Western Europe) involved 4413 people with HCV plus HIV and 10,213 with HIV alone. The 27 cART studies (12 US/Canada/Puerto Rico, 9 Western Europe) included 25,319 coinfected people and 61,697 with HIV alone. In the pre-cART era, a random effects model determined that coinfected people had a lower overall mortality risk than people infected only with HIV (risk ratio 0.68, 95% CI 0.53 to 0.87). (A single large study drove that outcome; because that study included only in-hospital patients, the meta-analysis authors believe it may suffer from survival bias. (13))

After cART arrived, that risk flip-flopped. Statistical analysis adjusted for cART use, proportion of IDUs, study duration, and sex determined that coinfected people had a 35% higher overall death risk than monoinfected people in the cART era (RR 1.35, 95% CI 1.11 to 1.6) (Table 4, Figure 1). And, notably, the risk of AIDS in the cART era did not differ significantly between coinfected and monoinfected people (RR 1.12, 95% CI 0.82 to 1.51). "Given the lack of an association between progression to AIDS and HCV coinfection," the authors observed, "the major contributor to mortality among coinfected subjects during the HAART era is likely to be liver disease." (13)

Risk of all-cause mortality with vs without HCV A 5974-person Spanish HIV cohort study published after this meta-analysis found that all-cause mortality in HCV-negative people fell by half from 1997-2003 to 2004-2008 (adjusted incidence rate ratio [aIRR] 0.52, 95% CI 0.32 to 0.85). (44) But among HCV-coinfected people, overall mortality rose nonsignificantly from 1997-2003 to 2004-2008 (aIRR 1.27, 95% CI 0.90 to 1.79). A recent analysis of the largely European CASCADE collaboration included 936 coinfected people and 833 monoinfected people in the pre-cART era, and 1767 coinfected and 6907 monoinfected people in the cART era. (45) All-cause pre-cART mortality within 15 years of HIV seroconversion was higher, but not significantly higher, in the monoinfected group (78% versus 58%). In the cART era, in contrast, a significantly higher proportion of coinfected people died of any cause within 15 years of HIV seroconversion (35%, 95% CI 31% to 39%, versus 11%, 95% CI 9% to 14%). After statistical adjustment for HIV risk group, age, and sex, coinfected people had an 84% higher risk of death from any cause than did monoinfected people in the cART era (adjusted hazard ratio [aHR] 1.84, 95% CI 1.16 to 2.93) (Figure 1).

AIDS-related mortality dropped sharply in both coinfected and monoinfected people in the cART era, although AIDS (and non-natural causes) remained the leading causes of death in the coinfected group, while AIDS (and natural causes) remained the leading causes in the monoinfected group. (45) But unlike the meta-analysis, (13) the CASCADE study determined that coinfected people had a higher risk of AIDS death than monoinfected people--regardless of HIV transmission group--in the cART era. (45)

The CASCADE team speculated that this difference from the meta-analysis could reflect "differences in follow-up duration, inability to correct for duration of HIV infection, different statistical methods, and [racial/ethnic] differences in patient population." (45) Why would AIDS-related mortality be significantly greater in the coinfected group after cART's advent? The CASCADE team speculated that higher T-cell activation with HCV infection could upset immune function in coinfected people as cART quells HIV-induced immune activation in both coinfected and monoinfected people. Cirrhosis and advanced liver disease in coinfected people would further promote AIDS conditions. So although AIDS deaths dropped steeply in both coinfected and monoinfected people, the drop was less acute in the coinfected group. Finally, although liver-related mortality fell among coinfected people in the cART era compared with earlier years, coinfected people still died more from liver-specific causes than monoinfected people after cART arrived.

These two large analyses concurred on the key finding that HCV/HIV-coinfected people began running a higher risk of death from any cause than did HIV-monoinfected people once cART arrived. The CASCADE investigators proposed that "an increased risk of both HIV and/or AIDS and hepatitis or liver-related mortality among co-infected individuals in the cART era might suggest that co-infected patients should start HIV and HCV treatment sooner after diagnosis to reduce the likelihood of disease progression, even in the absence of liver fibrosis," (45) a stance reflecting current US guidelines (Table 2). (30)

A large EuroSIDA study confirmed the higher risk of death from any cause with HCV/HIV coinfection than with HIV infection alone (Table 4). (26) The study involved 5957 HIV-positive people, 1960 of them (33%) positive for HCV antibody. People began entering EuroSIDA in May 2004, when 3117 participants signed up. Another 1365 people joined in December 1995, the cusp of the cART era. A further 6747 people enrolled in four more waves through 2003. Follow-up for the HCV/HIV analysis continued until the autumn of 2004, by which time everyone in this analysis had started cART. Median follow-up measured 45 months in the HCV/HIV group and 32 months in the HIV-only group.

The EuroSIDA team used two multivariate models to calculate the impact of HCV coinfection on virologic response, CD4 gains, progression to AIDS, any death, and liver-related death: The first model considered fixed factors known at baseline, and the second model considered updated CD4 count, cART initiation, and diagnosis of a new AIDS illness. (26) HCV coinfection raised the risk of any death 41% in the fixed-factor model (IRR 1.41, 95% CI 1.13 to 1.76, P = 0.0024) and 80%) in the updated factor model (IRR 1.80, 95% CI 1.44 to 2.25, P < 0.0001). The investigators attributed these higher death rates to more than a 10-fold higher risk of liver-related death with HCV in either statistical model.

Two US studies do not link coinfection to higher death risk

But two US studies saw no link between HCV and a higher death risk in people with HIV. (20-46) A 10-city US study involved 10,481 US adults and adolescents, 2024 of them (19%) with a positive HCV test (Table 4). (46) Only 7% of the HIV-negative group and 2% of the HCV positive group were younger than 24. Two thirds of the HCV-positive group and almost three quarters of the negative group took cART (66.2% versus 71.2%, P < 0.0001) during a median follow-up of 1.9 years between 1998 and 2004. The HCV group included a significantly higher proportion of IDUs (47.4% versus 7.5%), as well as gay/bisexual men who injected drugs (11.8% versus 3.9%) (P < 0.0001) and people who injected drugs in the past 6 months (13.2% versus 2.0%, P < 0.0001).

During follow-up, 16% of HCV-coinfected people died, compared with 9.3% of the HCV-negative group. Statistical analysis controlling for alcoholism, alcoholic hepatitis, drug-induced hepatitis, being prescribed ART, a previous AIDS diagnosis, lower CD4 cell count, and age found that coinfection did not affect the risk of death (aHR 1.1, 95% CI 0.9 to 1.2, P = 0.38).

A study of people in care from January 1995 to January 2001 at the Johns Hopkins Hospital HIV Clinic in Baltimore found that HCV coinfection raised the risk of death in certain analyses but not in others (Table 4). (20) The 1955 HIV-positive people in this study included 873 (44%) with a repeatedly reactive HCV antibody test. Median follow-up lasted 2.19 years in the HCV group and 2.0 years in the HCV-negative group. The HCV group was significantly older and included a higher proportion of African Americans (86% versus 68%, P < 0.001) and a higher proportion of IDUs (85% versus 13%, P < 0.001). People with HCV had a significantly lower baseline CD4 count (237 versus 266 cells/[mm.sup.3], P = 0.02). No one had an AIDS illness before enrollment.

During follow-up 153 HCV-positive people (17.5%) and 168 HCV-negative people (15.5%) died. (20) Cox proportional hazards regression analysis (adjusted for HCV status, age, sex, race, baseline CD4 count, and baseline viral load) discerned no mortality risk difference with versus without HCV (RH 1.05, 95% CI 0.85 to 1.30). Analysis limited to 1199 people who eventually took cART also found no mortality difference with versus without HCV (RH 1.22, 95% CI 0.22 to 1.61). The same proved true in 208 people with cART-controlled HIV replication, defined as having a viral load below 400 in 75% or more measurements (RH 1.49, 95% CI 0.33 to 6.68). HCV did boost the risk of death in 429 people with a pre-cART CD4 count between 50 and 200 cells/ [mm.sup.3] (RH 1.51, 95% CI 1.01 to 2.27) and in those in this subgroup who received cART (RH 1.85, 95% CI 1.11 to 3.07). (20) But in this 50-200 CD4 subgroup, multivariate Cox regression also adjusted for cART use and HIV suppression saw no HCV impact on death risk (RH 1.01, 95% CI 0.65 to 1.56). Notably, the Hopkins team found that 187 of all 1199 people (15.6%) taking cART died, compared with 6 of 208 (2.9%) with well-controlled HIV replication. In the final multivariate model, longer time on cART independently halved the risk of death (RH 0.47, 95% CI 0.36 to 0.63), while more clinic visits with a detectable HIV load raised the death risk 8 times (RH 7.96, 95% CI 2.00 to 31.66).

Why do the two US studies (20,46) find no association between HCV coinfection and death while the cARTera meta-analysis, (13) the European CASCADE study, (45) and the EuroSIDA study (26) do? The list of differences between these analyses could run several paragraphs, starting with utterly different populations, formats, years of cART, and statistical methods, then grinding down to nitty-gritties like confounders controlled for versus not considered. The meta-analysis, CASCADE, and EuroSIDA combined included three times as many people as the Hopkins and 10-city US study combined. The Hopkins study (20) and the 10city study (46) each had about 2 years of follow-up for people with and without HIV. EuroSIDA had 3.75 years of follow-up in the HCV group and 2.7 in the HCV-negative group. In 27 cART-era meta-analysis study, (13) 8 studies had 1 to 3 years of follow-up, 10 had more than 3, and 5 did not report follow-up. CASCADE did not report follow-up years. So the studies finding that HCV coinfection shortened survival generally had longer follow-up than the studies that did not. The 10-city US study controlled for alcoholism, alcoholic hepatitis, and drug-induced hepatitis, whereas CASCADE and EuroSIDA did not. This US study did not control for injection drug use or recent injection drug use, both of which were significantly more prevalent in the HCV-positive group, though controlling for drug-induced hepatitis may amount to the same thing.

One could go on, but probably to little avail. If compelled to boil all these data down to a single take-home dictate, it might be, HCV coinfection may shorten survival in people with HIV, and clinicians should do what they can to improve survival chances, notably by starting cART as quickly as feasible, working with an HIV/liver consultant to plan an optimal HCV treatment program, and working with coinfected patients to limit other prime risk factors, such as drinking, smoking, and injection drug use.

SMART trial investigators added a compelling footnote to these analyses of how HCV coinfection affects mortality. (47) SMART famously found that people who suspended cART based on CD4 count had a higher risk of opportunistic disease and/or death from any cause than did people who took continuous cART. Of the 5472 study participants, 930 (17%) had HCV or HBV coinfection. Coinfected people had more than a tripled risk of death due to nonopportunistic causes compared with monoinfected people (HR 3.6, 95% CI 2.3 to 5.6), while the risk of death from opportunistic disease proved comparable in coinfected and monoinfected people. Almost half of all nonopportunistic deaths in SMART involved coinfected people, even though they made up only 17% of the study group. Substance abuse and non-AIDS cancer were the two most-identified causes of nonopportunistic death in coinfected SMART participants. The SMART team concluded that "interruption of antiretroviral therapy is particularly unsafe in persons with hepatitis virus coinfection." (47)


As with studies analyzing the impact of HCV/HIV coinfection on mortality, studies examining how HCV affects chances of HIV disease progression tell different stories before and after people started taking cART (Table S). In pre-cART days, a 416-person Italian study (48) and a 1649-person analysis of Canadians, Australians, Europeans, and South Africans enrolled in the CAESAR trial (27) determined that HCV infection had no impact on CD4 declines or progression to AIDS. Everyone with HIV--with or without HCV--had an inexorably downward disease course.

But that changed when cART came along. Triple therapy usually halted HIV disease progression by bolstering immune function and putting HIV replication in check. Yet studies began showing that cART did not rescue HCV-coinfected people as consistently as patients without the hepatitis virus. With follow-up beginning soon after cART came online, a 1467-person study at a large London HIV clinic (21) and a 5397-person analysis of the Italian Icona cohort (29) found that HCV coinfection raised chances of CD4 tallies dwindling below 200 cells/[mm.sup.3] or a new AIDS diagnosis (Table 5). A study of 343 HIV-positive people in Saskatchewan--79% with a drug-injecting history and 77% with HCV--figured that HCV tripled chances that CD4s would dwindle below 200 cells/ [mm.sup.3] (HR 2.9, 95% CI 1.2 to 6.9).49

The 2009 meta-analysis of 7 HCV/HIV studies in Canada, Europe, the United States, and Taiwan during the cART era found that HCV infection barely budged chances of a new AIDS diagnosis when compared with HIV alone (aRR 1.12, 95% CI 0.82 to 1.51). (13) But this meta-analysis did not include the large Italian study that found more than a doubled risk of an AIDS diagnosis with versus without HCV, (29) and it did not include the small Saskatchewan study that linked HCV coinfection to a CD4 drop below 200 cells/[mm.sup.3] or a new AIDS diagnosis. (49) Adding those 5740 patients to the meta-analysis would have boosted the risk of HIV disease progression with HCV, perhaps into significant terrain. The meta-analysis did find that coinfection inflated chances of an AIDS diagnosis or death about 50% (aRR 1.49, 95% CI 1.08 to 2.05).

The 2013 CASCADE cohort analysis did not consider a new AIDS diagnosis or waning CD4 counts as an endpoint. (45) But HCV coinfection more than doubled or tripled chances of AIDS-related mortality in the cART era, depending on HIV transmission group (Table 5).

Together these studies (Table 5) offer compelling evidence that--as cART began to rescue people from AIDS--it left behind many coinfected with HCV. With these findings in mind, the CASCADE team stressed "the importance of early diagnosis of HCV infection in HIV-infected individuals and the need for routine screening of HCV among high-risk groups, including those not (yet) infected with HIV." (45) They proposed that their results "highlight the importance of interventions to increase the uptake of HCV treatment in co-infected individuals." Findings in multiple populations that HCV raises chances of AIDS or a falling CD4 count lend credence to data indicating that HCV boosts mortality in people with HIV, the issue examined in the preceding section.


HCV has a profound impact on mortality in people with HIV not only because it leaves many vulnerable to AIDS (preceding section), but also because it has far-flung repercussions on risk and progression of deadly non-AIDS diseases. Research indicates that HCV affects kidneys, heart, bones, brain, and eyes--all highly pregnable organs in people with HIV infection (Figure 2).

HCV coinfection did not heighten renal or cardiovascular disease prevalence in a 1996-2001 age-adjusted analysis of 823 HIV-positive people in the HIV Outpatient Study. (50) But more recent and larger analyses did find ties between HCV and damaged kidneys or heart. Analysis of 3441 cART-treated people enrolled in the SMART and ESPRIT trials included 473 (14%) positive for HCV antibody and 363 (10.5%) with detectable HCV RNA. (51) After adjustment for renal risk factors, statistical analysis determined that HCV coinfection bolstered odds of progressive chronic kidney disease (CKD) almost 75% (adjusted odds ratio [aOR] 1.72, 95% CI 1.07 to 2.76). People with low or undetectable HCV RNA had a CKD progression risk similar to that of HCV-negative people, but those with an HCV load above 800,000 IU/mL had tripled odds of progression (aOR 3.07, 95% CI 1.60 to 5.90).

An 8235-person EuroSIDA group included 2025 (25%) positive for HCV and 983 (12%) with detectable HCV RNA. (52) During follow-up starting in January 2004, CKD developed in 495 people (6%) for an incidence of 13.7 per 1000 person-years. After statistical adjustment for kidney risk factors, HCV positivity nearly doubled the risk of incident CKD (IRR 1.85, 95% CI 1.49 to 2.30, P < 0.0001). People who cleared their HCV had a CKD risk similar to that of HCV-negative people (IRR 1.17, 95% CI 0.65 to 2.09, P = 0.60). But people with HCV RNA between 615 and 500,000 IU/mL had almost a twice higher CKD incidence (IRR 1.88, 95% CI 1.31 to 2.71, P = 0.0006), and people with an HCV load above 500,000 IU/mL had more than a doubled risk of progression to CKD (IRR 2.10, 95% CI 1.54 to 2.87, P < 0.0001). Results of both studies (51,52) endorse calls for early HCV therapy in coinfected people.

HCV coinfection swelled risk of cardiovascular disease and acute myocardial infarction (MI) in a study of 19,424 US veterans, 32% of whom had HCV coinfection. (53) As in previous research, this study recorded lower cholesterol levels in people with HCV, but HCV-positive veterans had significantly higher rates of hypertension, type 2 diabetes, and smoking. Through more than 76,000 person-years of follow-up in the cART era (1996-2004), cardiovascular disease and acute MI incidence were significantly higher in HCV-coinfected veterans. After statistical adjustment for diabetes, hypertension, age, and cART duration, HCV inflated acute MI risk 25%, though that association stopped short of statistical significance (aHR 1.25, 95% CI 0.98 to 1.61, P = 0.072). HCV boosted cardiovascular disease risk 20%, and that association was significant (aHR 1.20, 95% CI 1.04 to 1.38, P = 0.013).

The French prospective APROCO-COPILOTE cohort involved 1281 people who began cART in 19971999, 26 of whom had 27 fractures during a median follow-up of 7.1 years between March 1997 and August 2007.54 Body mass index did not differ between those with and without a fracture, but people who broke a bone were more often heavy drinkers (44%> versus 19.5%), more likely to have HCV coinfection (48% versus 24.5%), and had a lower baseline CD4 count (194 versus 277 cells/[mm.sup.3]). Multivariate analysis determined that heavy drinkers had almost tripled odds of fracture (aOR 2.9, 95% CI 1.3 to 6.5). Fracture risk was even higher in people coinfected with HCV (aOR 3.6, 95% CI 1.6 to 8.1).

Both HCV and HIV penetrate the central nervous system, so there's no surprise that studies link HCV coinfection to neurologic problems, including neurocognitive impairment and neuroretinal disorder. A small study at the University of North Carolina, Chapel Hill documented worse visual memory and fine-motor functioning in 20 HCV/HIV-coinfected people than in 45 infected only with HIV before they started cART. (55) The groups had comparable HIV progression before treatment started, and no one had a history of neurologic conditions. Six months after cART began, follow-up neuropsychological testing in 13 coinfected and 31 monoinfected people indicated that coinfected people no longer had worse neurocognitive function than the monoinfected group.

A 1998-2010 study at two HIV clinics in Alberta, Canada involved 456 HIV-positive people without a substance abuse history, 91 of them (20%) positive for HCV. (56) The coinfected group had a higher prevalence of multiple neurologic disorders (60.4% versus 46.6%, P < 0.05) and a higher seizure frequency (28.6% versus 17.8%, P < 0.05). Seizure risk was independent of immune status in the coinfected group but not the monoinfected group. Symptomatic HIV-associated neurocognitive disorder (HAND) was more severe in coinfected than monoinfected people. Reflecting most studies reviewed in the mortality analysis above, a significantly higher proportion of people with than without HCV in the Alberta analysis died during the study period (24.2% versus 14.5%, P < 0.05). The coinfected group had a 2.4 times higher death risk after adjustment for demographic and clinical variables.

A 2013 study by researchers at New York's Mount Sinai Medical Center and Baltimore's Johns Hopkins University focused on 1576 HIV-positive people with no record of ocular opportunistic infection. (57) The group included 290 people (18%) with chronic HCV infection, 74 (5%) with cleared HCV infection, and 1212 (77%) with no HCV markers. The investigators counted 244 prevalent cases of HIV-associated neuroretinal disorder (15.5%)--visual impairment marked by reduced contrast sensitivity and reading ability. During a median follow-up of 4.9 years, neuroretinal disorder developed in another 263 people (17%). Statistical analysis adjusted for demographics, HIV treatment, liver function, and immune status determined that people with chronic HCV infection had 54% higher odds of prevalent neuroretinal disorder (95% CI 1.03 to 2.31) and 62% higher odds of incident neuroretinal disorder (95% CI 1.13 to 2.34) when compared with HCV-negative people.


Among 10 large studies analyzing antiretroviral response in people starting cART, five (including an 8-cohort meta-analysis (14)) found that HCV coinfection impaired CD4 or virologic response to cART, four did not, and one found an early impact on CD4 gain that disappeared over 4 years (17) (Table 6). No easy explanation of this disagreement screams for attention.

One of the no-impact studies, an analysis of 970 US veterans in a prospective cohort, (43) included a relatively low proportion of IDUs and assessed CD4 changes after only 6 months of treatment. But the other three no-impact studies, a Johns Hopkins cohort study, (20) a EuroSIDA study (26) and a 10-city US analysis, (46) had higher proportions of IDUs and longer follow-up. All told, the no-impact studies assessed 19,403 people, including 5163 (27%) positive for HCV. The five studies finding that HCV worsens response to cART tallied 14,110 participants, 4192 (30%) with HCV. Almost all cohort members in every study lived in Western Europe or the United States.

The 2005 meta-analysis focused on 8 cohorts of people starting cART from 1995 through the early 2000s. (14) After 48 weeks of treatment, people positive for HCV had a 33.4-cell lower CD4 gain than people negative for HCV. No single study had an undue influence on the results, and cART begun before or after the year 2000 did not affect the key finding. These investigators noted that their analysis is limited by an inability to determine pretreatment CD4 counts in the cohorts assessed. Also, seven of the eight studies that reported virologic response to cART saw no difference by HCV status.

The most recent analysis compared HCV-positive and negative people enrolled in four AIDS Clinical Trials Group (ACTG) trials of first-line cART. (5) All trials assessed contemporary cART regimens including efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. After substantial follow-up (median 132 weeks), HCV-positive people had worse virologic, CD4 count, and CD4 percent responses in adjusted analyses. They also ran a 50% higher risk of grade 3 or 4 safety events and a doubled risk of AIDS or death. Antiretroviral adherence was good in both the HCV-positive and negative groups. Strengths of this analysis, the researchers observed, include "randomization, rigorous study monitoring, and extensive and similar data collection." And the worse CD4 response with HCV held true when the investigators limited the analysis to people without virologic failure. The ACTG team noted that their study (like the meta-analysis (14)) sulfers from dependence on HCV antibody testing rather than HCV RNA assessment and the relatively small proportion of HCV-positive people.

This ACTG analysis checked cART responses through 2.5 years of therapy. (5) The (earlier and smaller) Swiss HIV Cohort Study (SHCS) reckoned cART responses through 4 years of treatment and determined that HCV positivity did not imperil CD4 gains over that span. (17) The SHCS analysis did find worse 1-year CD4 gains in coinfected people (Table 6), but that deficit disappeared with continued cART.

The Canadian Co-infection Cohort Study was the only study that distinguished between HCV RNA-positive people with chronic HCV infection and HCV antibody-positive people with cleared infection. (6) This 16-center study monitoring people from 2003 through 2009 found that those who cleared their HCV gained 26 CD4 cells/[mm.sup.3] yearly, compared with a meager 4 cells/[mm.sup.3] yearly in the chronically infected HCV RNA-positive group (P < 0.001). Researchers figure that 85% of HCV antibody-positive people have chronic infection. (58) But the remaining 15%- could have some impact on results of the 7 studies relying solely on HCV antibody testing.

If one believes the apparently preponderant evidence that HCV coinfection heightens the risk of AIDS (Table 5), believing that HCV does not affect CD4 counts or viral load requires some gymnastic reasoning.


Can the harried clinician put all these HCV and HIV pieces together to decide how HCV affects HIV progression? A quick check of the reference list indicates that--after excluding HIV care guidelines--there are a lot of pieces: 55 if you count each study cited so far, many more if you pick out key data points from each study. One answer--as frivolous as sounds--is it doesn't matter which studies are right and which wrong (or less right).

A first step toward groping one's way through the research labyrinth to slay the data-spouting minotaur (Figure 3) is to ask whether an HCV impact on HIV's course makes pathophysiologic sense. It does:

* Activated CD4 and CD8 cells (reflecting poorly controlled infection and signaling progression) reach higher levels in HCV/HIV-coinfected people than in those infected with only one or the other virus. (59) T-cell activation and exhaustion in this 58-person study correlated with HCV RNA load.

* Activated CD8 cell percentages proved higher in women positive for HIV, HCV antibody, and HCV RNA than in women positive for HIV but not HCV antibody in a 218-woman study. (60)

* HCV-positive women with measurable HCV RNA had significantly higher levels of activated CDS cells and a higher AIDS incidence than HCV-negative women, according to results of a 1307-woman analysis. (61)

* HCV coinfection boosted T-lymphocyte apoptosis (cell death) in 30 HIV-positive people not taking antiretrovirals more than in 31 people infected only with HIV. (62)

Thus reassured, the clinician can acknowledge that a mountain of data--reasonably interpreted--says HCV infection makes people with HIV get sick and die faster than people without HCV. Yet there's no denying that another mountain of data says the opposite. Does it matter which mountain one decides to plant one's flag upon? The apparent answer seems to be "certainly"--because the outcomes are sickness versus health, life versus death.

But from a different perspective--one that offers a view of the minotaur's maze from above rather than within (Figure 3)--debates over the clinical impact of HCV on HIV disease are academic. Would anyone suggest that failure to find an association between HCV and HIV disease progression in some studies means clinicians can relax when treating coinfected people? Or stop worrying about skyscraping HCV loads? Or delay deciding how and when to treat HCV infection?

With direct-acting antivirals (DAAs) already on hand and rapidly growing more numerous (see the first article in this issue of RITA!), would anyone suggest delaying HCV therapy and denying a coinfected person a 90% or higher chance of cure makes sense because HCV does not, or may not, worsen the course of HIV infection? DAAs have not only transformed treatment of HCV infection; they have also radically reshaped interpretation of how HCV and HIV interact to make someone sicker or closer to death. One might delay DAA therapy to wait for an appropriate all-DAA regimen, but not because of HCV's impact on HIV.

What about conflicting data on how HCV affects antiretroviral response? If a clinician believes the five studies that saw no impact of HCV coinfection on cART response (Table 6), that clinician will have no concerns over timing treatment of HCV and HIV in the same person. If a clinician believes the four studies (including one meta-analysis) that found a diminished response to cART in people with HCV, that clinician may want to start cART first in people with advanced HIV infection (as suggested in US guidelines (30)) and probably wants to monitor antiretroviral response more closely in people being treated for HIV and HCV at the same time.

But for both sets of providers, the imminent arrival of multiple-DAA regimens may largely render cART timing decisions moot. Delaying cART for 6 months or more in HCV-coinfected people taking pegylated interferon plus ribavirin may be an unpalatable option--or completely out of the question--for patients with low CD4 counts or clinical AIDS. But if DAA combinations can cure HCV infection in 6 to 12 weeks, many more HIV-positive people may be candidates for (briefly) delayed cART during HCV therapy.


(1.) Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979-1991.

(2.) Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158:658-666.

(3.) Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779-789.

(4.) Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008;47:221-225.

(5.) Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS. 2013;27:2725-2734.

(6.) Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB. Impact of hepatitis C viral replication on CD4 T-lymphocytc progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS. 2010;24:1857-1865.

(7.) Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? JAMA. 2002;288:241-243.

(8.) Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8:12-22.

(9.) Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.

(10.) De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162:2125-2132.

(11.) Lincoln D, Petoumenos K, Dore G. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003;4:241-249.

(12.) Seminari E, Tinelli C, Ravasi G, et al. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res 2010;8:186-193.

(13.) Chen T, Ding EL, Seage GR III, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49:1605-1615.

(14.) Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713-720.

(15.) Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169-1177.

(16.) Motta D, Brianese N, Foca E, et al. Virological effectiveness and CD4 T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Res Ther. 2012;9:18.

(17.) Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187-2195.

(18.) Agbaji O, Thio CL, Meloni S, et al. Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr. 2013;62:204-207.

(19.) Matthews GV, Dore GJ. HIV and hepatitis C coinfection./Gastroenterol Hepatol. 2008;23:1000-1008.

(20.) Sulkowski MS, Moore RD, Meehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.

(21.) Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1- infected individuals does not accelerate a decrease in the CD4 cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005;41:906-911.

(22.) Weimer LE, Fragola V, Floridia M, et al. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection./Antimicrob Chemother. 2013;68:193-199.

(23.) Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus co-infection. HIV Med. 2012;13:127-131.

(24.) Than N, Sungkanuparph S, Maek-A-Nantawat W, Kaewkungwal J, Pitisuttithum P. Comparison of clinical outcomes between HIV-infected patients with and without HCV coinfection in a resource-limited setting. Southeast Asian J Trop Med Public Health. 2011;43:646-651.

(25.) Collazos J, Carton JA, Asensi V. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. HIV Med. 2011; 12:308-315.

(26.) Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy J Infect Dis. 2005;192:992-1002.

(27.) Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C co-infection within the CAESAR study. HIV Med. 2004;5:174-179.

(28.) Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039-2045.

(29.) Monforte AD, Cozzi-Lepri A, Castagna A, et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis. 2009;49:612-622.

(30.) Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents. February 12, 2013. http://www.aidsinfo.nih.gOv/guidelines/html/l/adult-and-adolescent-arv-guidelines/0

(31.) Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1- 10.

(32.) US Department of Health and Human Services Health Resources and Services Administration. Guide for HIV/AIDS clinical care. January 2011.

(33.) Department of Health and Human Services (DHHS) Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. July 31, 2012.

(34.) Klein M. New treatment options for HIV-hepatitis C co-infection. 4th International Workshop on HIV & Women, January 13-14, 2014, Washington DC. Invited lecture.

(35.) Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29:150-154.

(36.) Hershow RC, O'Driscoll PT, Handelsman E, et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women; Women and Infants Transmission Study. Clin Infect Dis. 2005;40:859-867.

(37.) Gichangi A, Vach W. The analysis of competing risks data; A guided tour. Department of Statistics, University of Southern Denmark. Odense. 2005.

(38.) Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature. 1989;338:251-253.

(39.) Osmond DH. Epidemiology of disease progression in HIV. HIV InSite Knowledge Base Chapter. 1998.

(40.) Zwahlen M, Egger M. Progression and mortality of untreated HIV-positive individuals living in resource- limited settings: update of literature review and evidence synthesis. University of Berne, Switzerland. 2006.

(41.) Centers for Disease Control and Prevention. Hepatitis C information for the public. http://wxuw.cdc.gOv/hepatitis/c/cfaq.htm

(42.) Macias J, Pineda JA, Leal M, et al. Influence of hepatitis C virus infection on the mortality of antiretroviral- treated patients with HIV disease. Eur J Clin Microbiol Infect Dis. 1998;17:167-170.

(43.) Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004;39:1507-1513.

(44.) Berenguer J, Alejos B, Hernando V, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS. 2013;26:2241-2246.

(45.) van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. 2013;144:751-760.

(46.) Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006;20:1171-1179.

(47.) Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis. 2008;47:1468-1475.

(48.) Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study./Infect Dis. 1995;172:1503-1508.

(49.) Konrad S, Skinner S, Kazadi GB, Gartner K, Lim HJ. HIV disease progression to CD4 count <200 cells/[mu]l. and death in Saskatoon, Saskatchewan. Can J Infect Dis Med Microbiol. 2013;24:97-101.

(50.) Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;36:363-367.

(51.) Mocroft A, Neuhaus J, Peters L, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One. 2012;7:e40245.

(52.) Peters L, Grint D, Lundgren JD, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26:1917-1926.

(53.) Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-468.

(54.) Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV-1-infected adults. AIDS. 2009;23:1021-1024.

(55.) Parsons TD, Tucker KA, Hall CD, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co- infection. AIDS. 2006;20:1591-1595.

(56.) Vivithanaporn P, Nclles K, DeBlock L, Newman SC, Gill MJ, Power C. Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS./ Neurol Sci. 2012;312:45-51.

(57.) Branch AD, Drye I.T, Van Natta ML, et al. Evaluation of hepatitis C virus as a risk factor for HIV- associated neuroretinal disorder. Clin Infect Dis. 2013;57:1618-1625.

(58.) Thomas D, Astemborski J, Rai R, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.

(59.) Feuth T, Arends JE, Fransen JH, et al. Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection. PLoS One. 2013;8:e59302.

(60.) Kovacs A, Al-Harthi I., Christensen S, Mack W, Cohen M, Landay A. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus./ Infect Dis. 2008;197:1402-1407.

(61.) Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus./ Infect Dis. 2010;201:823-834.

(62.) Nunez M, Soriano V, L6pez M, et al. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV- infected patients. Clin Infect Dis. 2006;43:1209-1212.

care. January 2011.

Table 1. Screening and prevention guidelines for HCV and HIV


Everyone with HIV should be screened for HCV infection when
entering care, preferably before starting cART (DHHS Adult), (30)
and annually thereafter (HIVMA/IDSA). (31)

People positive for HCV antibody should have HCV RNA measured to
determine whether HCV infection is active (HIVMA/IDSA). (31)

HCV RNA should be measured in HCV antibody-negative people with a
history of injection drug use or unexplained increased serum
transaminases because HCV antibodies do not develop in
approximately 6% of HCV/HIV-coinfected people (HIVMA/IDSA). (31)

Infants born to HCV- or HBV-infected women should be screened for
HCV and HBV. Infants can be tested for HCV RNA after age 2 months
and for HCV antibody after 18 months of age (HIVMA/IDSA). (31)


To assess kidney function, HCV/HIV-coinfected people should be
screened for proteinuria when they begin care and annually
thereafter (HIVMA/IDSA). (31)

All HCV/HIV-coinfected people should be tested for hepatitis A
virus (HAV) and hepatitis B virus (HBV) and vaccinated if not
immune (HRSA). (32)

HCV/HI V-coinfected people vaccinated against H BV in the past
should have their anti-H BV titer checked to make sure they remain
protected (HRSA). (32)

Patient counseling

People with HCV infection should be counseled to avoid alcohol and
medications toxic to the liver, including fluconazole, isoniazid,
and large doses of acetaminophen (HRSA). (32)

People with HCV infection should be counseled to reduce risk of HCV
transmission through unprotected sex, perinatal exposure, or
sharing drug-injecting equipment, razors, tattoo equipment, or sex
toys (HRSA). (32)

See the 1-page patient guide at the end of this article.

Table 2. HIV and HCV care guidelines for people with coinfection

Combination antiretroviral therapy (cART) should be considered for
coinfected patients regardless of CD4 count because cART may slow
liver disease progression by preserving or restoring immune
function and reducing HIV-related immune activation (DHHS Adult).

Liver function should be monitored closely in coinfected people on
cART (HRSA). (32)

Consideration of potential drug-drug interactions and overlapping
toxicides should guide antiretroviral selection in coinfected
people receiving treatment for HCV infection (DHHS Adult). (30)

Because of pill burden, drug-drug interactions, and overlapping
toxicides when treating coinfected people, some clinicians may
choose to defer cART until antiretroviral-naive people with a CD4
count at or above 500 cells/[mm.sup.3] complete anti-HCV therapy *
(DHHS Adult). (30)

For people with a CD4 count below 200 cells/[mm.sup.3], it may be
preferable to start cART first and begin HCV therapy after the CD4
count rises (DHHS Adult). (30)

Interferon alfa and pegylated interferon are not recommended during
pregnancy, and ribavirin is contraindicated during pregnancy (DHHS
Perinatal). (33)

Men and women taking ribavirin should use contraception
consistently during ribavirin therapy and for 6 months after
completing ribavirin therapy (HRSA). (32)

Treatment of HCV infection in HIV-positive people is evolving
rapidly as direct-acting antivirals (DAAs) become available and
their interactions with antiretrovirals are defined. For the latest
treatment advice, see the table "Unique Patient Populations:
HIV/HCV Coinfection" in Recommendations for Testing, Managing, and
Treating Hepatitis C, from the Infectious Diseases Society of
America: full-report-view. Also see the
article on DAAs in this issue of Research Initiative, Treatment
Action! and the interview with Douglas Dieterich.

People with HCV infection who inject drugs should be strongly
counseled to enter a treatment program to end their dependence
(HRSA). (32)

* Recent and ongoing approval of stronger direct-acting antivirals
(DAAs) for HCV infection with 8- to 24-week courses could
strengthen the rationale for treating HCV infection before starting
cART. (34)

Table 3. Impact of HCV infection on survival in Atlanta VA Cohort
before cART and with cART

                       Staples (35)

Observation            January 1992 through
period                 May 1997

                       HCV plus HIV      HIV only
                       (n = 115)         (n = 235)

Had AIDS               81 (70%)          164 (70%)

Took cART              19(16%) *         50 (21%) *

Died                   24 (21%)          46 (20%)

Time from HIV          No difference by Cox
Dx to death            proportional hazards model

Time from AIDS         No difference by Cox
Dx to death            proportional hazards model

                       Anderson (43)

Observation            January 1997 through
period                 May 2001

                       HCV plus HIV         HIV only
                       (n = 306)            (n = 664)

Had AIDS               213 (70%)            433 (65%)

Took cART              199 (65%)            509 (77%)
                       ([dagger])           ([dagger])

Died                   67 (22%)             72(11%)
                       ([double dagger])    ([double dagger])

Time from HIV          aHR HCV+ vs HCV-: 2.47
Dx to death            (95% CI 1.26 to 4.82, P = 0.0085)

Time from AIDS         aHR HCV+ vs HCV-: 1.84 (95% CI
Dx to death            1.09 to 3.10, P = 0.022)

(a) HR, adjusted hazard ratio; Dx, diagnosis.

* Reported as protease inhibitor use.

([dagger]) P = 0.001.

([double dagger]) P < 0.0001.

Table 4. Five studies of HCV mortality impact in cART era

Author                 n, years               Population

Sulkowski (2002)       1995, 873 (44%)        Prospective cohort
(20)                   HCV +;                 of patients without
HCV does not           1995-2001;             AIDS starting cART;
have impact            median follow-         85% of HCV+, 13%
                       up 2.19 y              HIV-1DU
                       in HCV+,
                       2.00 y in HCV-

Rockstroh (2005)       5957, 1960 (33%)       Prospective study of
(26)                   HCV+; 1994-            EuroSIDA cohort;
HCV has impact         2004; follow-up        77.5% of HCV+,
                       3.75 y in HCV+,        3.2% HCV- IDU
                       2.7 y in HCV-

Sullivan (2006) (46)   10,481, 2024           Adult and Adolescent
                       (19%) HCV+;            Spectrum of HIV
HCV does not           1998-2004;             Disease participants
have impact            follow-up 1.9 y        starting cART; 47%
                                              HCV+, 7.5% HCV-

Chen (2009) (13)       87,016, 21,607         Meta-analysis of
                       (25%) HCV + ;          cART patients in 27
HCV has impact         1996-2004;             trials; 3%-64% IDU
                       8 studies 1-3 y
                       follow-up, 10
                       >3 y, 5 did not
                       report follow-up

van der Helm           8674, 1767             Europeans and
(201S) (45)            (20%) HCV+;            Canadians with
                       Pre-1989-2007          known date of
HCV has impact                                HIV seroconversion

Author                 Site(s)           Key outcomes *

Sulkowski (2002)       Baltimore         In cART-treated people
(20)                                     with a baseline CD4 count
HCV does not                             of 50-200, HCV raised
have impact                              death risk (RH 1.85, 95%
                                         Cl 1.11 to 3.07); in final
                                         model including cART
                                         use and HIV suppression,
                                         HCV had no impact on
                                         mortality (RH 1.01,95%
                                         Cl 0.65 to 1.56).

Rockstroh (2005)       Europe,           HCV raised risk of
(26)                   Israel            any-cause death in
HCV has impact                           fixed-factor model
                                         (IRR 1.41, 95% Cl 1.13
                                         to 1.76, P = 0.0024) and
                                         updated factor model
                                         (IRR 1.80, 95% Cl 1.44
                                         to 2.25, P < 0.0001),
                                         largely because of
                                         liver-related death.

Sullivan (2006) (46)   10 US cities      HCV did not raise risk of
                                         death (HR 1.1, 95% Cl 0.9
HCV does not                             to 1.2, P = 0.38).
have impact

Chen (2009) (13)       12 studies in     HCV raised risk of death
                       US, Canada,       (RR 1.35, 95% CI 1.11
HCV has impact         Puerto Rico;      to 1.6).
                       9 studies W

van der Helm           Europe,           HCV raised risk of death
(201S) (45)            Canada            (HR 1.84, 95% CI 1.16
                                         to 2.93).
HCV has impact

HR, hazard ratio; IDU, injection drug user; IRR, incidence rate ratio;
RH, relative hazard.

Table 5. Impact of HCV on HIV disease progression

Author            n              Population            Site(s)

Dorrucci          416, 214       AIDS-free, IDU        Italy
(1995) (48)       (51%)          or sexual
                  HCV+           transmission;
                                 known HIV sero-
                                 conversion date

Amin (2004)       1649, 265      People adding         Canada,
(27)              (16%)          3TC or 3TC/           Australia,
                  HCV+           loviride to single    Europe,
                                 or dual               South Africa

Stebbing          1467, 85       Patients with >200    Chelsea and
(2005) (21)       (6%) HCV +     CD4s in care since    Westminster
                                 cART availability     Hospital,
                                 in 1/1996             London

d'Arminio         5397, 2421     Icona cohort          Italy
Monforte          (49%)          patients enrolled
(2009) (29)       HCV+           when ART-naive

Konrad            343, 264       Mainly (79%) IDU      Two clinics in
(2013) (49)       (77%)          HIV+ population       Saskatchewan

Chen (2009)       21,607,        Meta-analysis of      7 studies
(13)              5334 (25%)     cART patients         in Canada,
                  HCV+                                 Europe, US,

van der Helm      9164, 2015     Europeans and         Europe,
(2013) (45)       (22%)          Canadians with        Canada
                  HCV+           known date of
                                 HIV seroconver-

Author            Year(s)          Key outcomes

Dorrucci          Pre-cART         HCV had no impact
(1995) (48)       longi-tudinal    on progression to
                  study            AIDS or CD4
                                   decline <100.

Amin (2004)       Pre-cART         Median change in
(27)              1995-1996        CD4 count and pro-
                  (52-wk FU)       gression to new AIDS
                                   event similar with/
                                   without coinfection.

Stebbing          1996-2005        HCV raised chance
(2005) (21)                        of <200 CD4s or first
                                   AIDS event (aHR
                                   1.52, 95% CI 1.07 to
                                   2.17, P = 0.019).

d'Arminio         1997-2008        HCV raised chances
Monforte                           of AIDS diagnosis
(2009) (29)                        (aRR 2.61, 95% CI
                                   1.88 to 3.61). *

Konrad            Diagnosed        HCV tripled risk of
(2013) (49)       2005-2010        CD4 decline <200
                                   (HR 2.9, 95% CI 1.2
                                   to 6.9).

Chen (2009)       1996-2004        In pooled analysis,
(13)                               HCV did not raise
                                   chance of new AIDS
                                   diagnosis (aRR 1.12,
                                   95% CI 0.82 to

van der Helm      Pre-1989-2007    HCV raised chances
(2013) (45)                        of AIDS-related
                                   mortality in cART
                                   era in IDUs (aHR
                                   2.43), MSM (aHR
                                   3.11), and others
                                   ([double dagger])
                                   (aHR 3.43).

aRR, adjusted relative rate; FU, follow-up; MSM, men who have sex with

* AIDS-defining illnesses included bacterial infection (aRR 3.15, 95%
CI 1.76 to 5.67), HIV-related disease (wasting and dementia, aRR 2.68,
95% CI 1.03 to 6.97), and mycotic disease (aRR 3.87, 95% CI, 2.28 to

([dagger]) Did not include d'Arminio Monforte (29) or Konrad. (49)

([paragraph]) Analysis of 7 other studies defining progression as
either an AIDS diagnosis or death determined that HCV coinfection
raised the risk of progression almost 50% (aRR 1.49, 95% CI 1.08 to

([double dagger]) People infected heterosexually or via blood

Table 6. Impact of HCV coinfection on response to cART

Author            n              Population             Site(s)

Sulkowski         1995, 873      Prospective cohort     Baltimore
(2002) (20)       (44%) HCV +    of patients with-
                                 out AIDS starting
HCV does not                     cART; 85% of
have impact                      HCV+ IDU

De Luca           1320, 600      Prospective study      Italy
(2002) (10)       (45%) HCV +    in Icona cohort
                                 patients starting
HCV has                          cART, 39% IDU

Kaufmann          985 on         Prospective Swiss      Switzerland
(2003) (17)       continous      HIV Cohort
                  cART, 300      Study patients
HCV has           (30.5%)        starting cART,
transient         HCV+           23% IDU

Anderson          970, 306       Atlanta VA Cohort      Atlanta area
(2004) (43)       (32%) HCV +    Study patients
                                 starting cART,
HCV does not                     22% IDU
have impact

Miller (2005)     6216, 2179     Meta-analysis of       Australia,
(14)              (35%) HCV +    patients starting      Canada,
HCV has                          cART in 8 cohorts,     France, Italy,
impact                           3% to 88% IDU          Spain, Swit-
                                                        zerland, US

Rockstroh         5957, 1960     Prospective study      Europe,
(2005) (26)       (33%) HCV +    of EuroSIDA            Israel
                                 cohort, 77.5%- of
HCV does not                     HCV+ IDU
have impact

Sullivan          10,481, 2024    Adult and              10 US cities
(2006) (46)       (19%) HCV +    Adolescent
                                 Spectrum of
HCV does not                     HIV Disease
have impact                      participants
                                 starting cART,
                                 47% HCV+ IDU

Potter (2010)     271 HCV+,      Canadian               16 centers in
(6)               236 (87%)      Co-infection           Canada
HCV has           with           Cohort Study
impact            detectable     participants
                  HCV RNA,       starting cART,
                  35 with        76% HCV RNA+
                  cleared HCV    and 71% HCV
                  RNA            RNA- IDU

Motta (2012)      3262, 863      Italian MASTER         9 centers in
(16)              (26%) HCV+     cohort starting        Italy
                                 cART in 2000-
HCV has                          2008

Hua (2013) (5)    3041, 279      Participants in        ACTG sites
                  (9%) HCV +     4 ACTGcART             in US
HCV has                          trials; 52%
impact                           HCV+ IDU

Author            Year(s)          Key outcomes *

Sulkowski         1995-2001,       HCV had no impact
(2002) (20)       median           on CD4-cell or
                  follow-up        CD4-percent gains
HCV does not      2.19 y with      with cART.
have impact       HCV, 2.00 y
                  without HCV

De Luca           Median 37        HCV+ had shorter
(2002) (10)       mo follow-up     time to AIDS or death
                  in 1997-2001     (aHR 1.55, 95% CI
HCV has                            1.00 to 2.41); mean
impact                             CD4 gain 30 cells/
                                   [mm.sup.3] less with HCV;
                                   no HCV impact on
                                   virologic response.

Kaufmann          Began cART       HCV+ had lower
(2003) (17)       1996-1997,       CD4 gain in first year
                  4 years          of cART (126 vs 151
HCV has           follow-up        cells/[mm.sup.3], P = 0.004)
transient                          but not after 4 years
impact                             of cART.

Anderson          1997-2001        HCV did not affect
(2004) (43)                        CD4 gain in first 6
                                   months of cART;
HCV does not                       IDU associated with
have impact                        lower CD4 gain.

Miller (2005)     1995-early       HCV + had mean
(14)              2000s            33.4 cells/[mm.sup.3] lower
HCV has                            gain through
impact                             48 weeks of cART.

Rockstroh         1994-2004        HCV had no impact
(2005) (26)                        on virologic or CD4
                                   response (measured
HCV does not                       as 50% or 50-cell
have impact                        increase).

Sullivan          1998-2004,       HCV did not affect
(2006) (46)       median 1.9 y     CD4 gains or
                  follow-up        virologic response
HCV does not                       in first 12 months
have impact                        of cART.

Potter (2010)     2003-2009        Yearly CD4 gain 4
(6)                                cells/[mm.sup.3] in HCV
HCV has                            RNA+ vs 26 cells/[mm.sup.3]
impact                             in HCV RNA-
                                   (P < 0.001).

Motta (2012)      Mean 4.3 y       HCV lowers odds of
(16)              follow-up        reaching <500 HIV
                                   RNA in 1st 8 mo (OR
HCV has                            0.612, P = 0.01 with
impact                             Pis, OR 0.717, P =
                                   0.006 with NNRTIs);
                                   HCV lowers odds of
                                   gaining 100 CD4s in
                                   8 months (OR 0.662,
                                   P = 0.003 with Pis,
                                   OR 0.595, P < 0.001
                                   with NNRTIs);
                                   HCV lowers 24-mo
                                   absolute CD4 gain.

Hua (2013) (5)    NR,-early        Through median
                  to late 2000s    132 wk follow-up,
HCV has                            HCV linked to
impact                             earlier virologic fail-
                                   ure (HR 1.43, 95%
                                   CI 1.07 to 1.91),
                                   smaller mean CD4
                                   increase (-33.8 cells/
                                   [mm.sup.3], 95% CI -52.2
                                   to -15.4), earlier
                                   grade 3/4 safety
                                   event (HR 1.51,
                                   95% CI 1.26 to 1.81),
                                   increased progression
                                   to AIDS or death
                                   (HR 2.10, 95% CI
                                   1.31 to 3.37).

* All analyses adjusted for potential confounders.

([dagger]) CD4 response analysis included only virologic responders.

ACTG, AIDS Clinical Trials Group; IDU, injection drug user; NR, not

Figure 1. A 37-study meta-analysis (13)
and a CASCADE Collaboration
study (45) both found a higher
risk of all-cause mortality with
HCV/HIV coinfection than with
HIV alone in the cART era but
not in the pre-cART era. (HR,
hazard ratio; RR; risk ratio.)

Pre-cART Meta      RR 0.68, 95% CI 0.53-0.87
cART-ere Meta      RR 1.35,95% CI 1.11-1.6
Pre-cART CASCADE   HR 0.75. 95% CI 0.41-1.37
cART-era CASCAD    HR 1.84,95% CI 1.16-2.93

Note: Table made from bar graph.
COPYRIGHT 2014 The Center for AIDS: Hope & Remembrance Project
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Perspectives; hepatitis C virus
Author:Mascolini, Mark
Publication:Research Initiative/Treatment Action!
Article Type:Report
Geographic Code:1USA
Date:Jun 22, 2014
Previous Article:Advice on using DAAs for patients with HCV/HIV coinfection: an interview with Douglas T. Dieterich, MD.
Next Article:Patient Guide: ten pointers for people with hepatitis C virus (HCV) and HIV infection.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters